MedChemExpress Anti-Cancer Compound Library

Click2Contact

MedChemExpress (MCE) is a supplier of high-quality chemicals, biochemicals and compound libraries, supporting the global scientific research community. MCE’s extensive product portfolio includes a range of screening libraries designed to accelerate drug discovery and development across multiple therapeutic areas. Among these, the Anti-Cancer Compound Library is a powerful tool for researchers seeking targeted solutions and novel cancer therapies.

The library offers over 8000 compounds with activity against both solid and haematologic tumours, making it suitable for high-throughput screening (HTS) and high-content screening (HCS).

This collection spans key cancer-related pathways such as apoptosis, cell cycle regulation and signal transduction. It also covers diverse signalling pathways — including kinase, GPCR and epigenetics — providing researchers with a comprehensive platform to explore and identify potential anti-cancer agents.

Many of the compounds have undergone rigorous clinical or preclinical evaluations, with some already approved by the FDA, highlighting their therapeutic potential.

The bioactivity and safety profiles of the compounds make the library a useful resource for advancing cancer research. Each compound is also validated for high purity and quality using NMR and LC/MS techniques, which should lead to precise and reproducible results.

A key advantage of MCE’s compound libraries is that users can fully customise a library to meet research needs from the type, quantity and concentrations of compounds and layout, offering the flexibility that researchers need to drive meaningful discoveries in oncology.

Click here to download the MedChemExpress Compounding Libraries brochure or contact Millennium Science at customerservice@mscience.com.au.